A Study of Two Inotuzumab Ozogamicin (InO) Doses in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Transplant Eligible Patients. A Phase 4, Open-Label, Randomized Study of Two Inotuzumab Ozogamicin Dose Levels
in Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Eligible for Hematopoietic Stem Cell Transplantation and Who Have Risk Factor(s) for Veno-Occlusive Disease.